7
Views
0
CrossRef citations to date
0
Altmetric
Plenary Sessions

Update on the benefit–risk profile of biologic therapy

Pages S31-S34 | Published online: 10 Jan 2014
 

Financial & competing interests disclosure

E Dauden has the following conflict of interests: Advisory Board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking and research support with the following pharmaceutical companies: Abbott, Astellas, Biogen, Galderma, GlaxoSmithKline, Janssen-Cilag, Leo Pharma, Merck-Serono, Novartis, Schering-Plough, Wyeth Pharmaceuticals and 3M. Writing assistance was provided by Steve Clissold PhD (Content Ed Net), with funding by Schering-Plough, USA. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.